[Vaccination against pneumococcal and influenza infections in children and adolescents with type 1 diabetes].

The effect of a Pneumo 23 vaccine against pneumococcal infection (n = 72; Subgroup 1) in combination with a Grippol vaccine against influenza infection (n = 28; Subgroup 2) was studied in children and adolescents with type 1 diabetes on insulin therapy. A control group consisted of 30 unvaccinated children. Unlike monovaccination, combined vaccination was ascertained to cause a significant reduction in the glycated hemoglobin following a year.

[The level of antibodies to pneumococcal vaccine in children and adolescents with type 1 diabetes].

The trend in the formation of postvaccinal antibodies (Ab) to a mixture of S. pneumoniae polysaccharides (PS) was studied in 100 Pneumo 23-vaccinated children and adolescents with type 1 diabetic (T1D) (Group 1, n = 72) and its combination with the subunit vaccine Grippol (Group 2, n = 28). Following 1-1.

[Autoantibodies after vaccination against pneumococcal and influenza infections in children and adolescents with type I diabetes mellitus].

Aim: To study the influence of vaccination against pneumococcal and influenza infections on the levels of autoantibodies to DNA, pancreatic and adrenal tissues as well as on populations of lymphocytes and levels of immunoglobulins in children and adolescents with type I diabetes mellitus (DM1).

Materials And Methods: One hundred and thirty children and adolescents 2 - 18 years of age were followed during 12 months. One hundred participants were vaccinated against pneumococcal infection with Pneumo 23 vaccine.

[Effect of vaccination against pneumococcal infection in children with type 1 diabetes mellitus].

Vaccination with polysaccharide pneumococcal vaccine "Pneumo 23" (Sanofi Pasteur, France) was performed in 31 children with type 1 diabetes mellitus (DM1) as well as in 19 children with respiratory tract diseases (asthma, chronic pneumonia), which formed comparison group. Fourty-three unvaccinated children with DM1 were included in the control group. Dynamics of IgG levels to mixture of pneumococcal polysaccharides (PS) included in the vaccine as well as to PS of serotypes 3, 6B, 9N, 23F, and to cell wall polysaccharides of Streptococcus pneumoniae were assessed.